Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
AssigneeExelixis, Inc.
InventorsJo Ann Wilson, Khalid Shah
Life of this patent
Estimating the term…
Abstract
The present invention is directed to processes for making and compositions containing quinolines such as formula I or pharmaceutically acceptable salts thereof wherein: X1 is H, Br, CI, or X2 is H, Br, CI, or n1 is 1-2; and n2 is 1-2.
Claims23
1-34. (canceled)
A pharmaceutical composition for oral administration comprising Compound IB:
- and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is a tablet or a capsule, and wherein the pharmaceutical composition contains 100 ppm or less of 6,7-dimethoxy-quinoline-4-ol.
The pharmaceutical composition of claim 1, wherein the pharmaceutical composition contains 50 ppm or less of 6,7-dimethoxy-quinoline-4-ol.
The pharmaceutical composition of claim 2, wherein the pharmaceutical composition contains 25 ppm or less of 6,7-dimethoxy-quinoline-4-ol.
The pharmaceutical composition of claim 3, wherein the pharmaceutical composition contains 10 ppm or less of 6,7-dimethoxy-quinoline-4-ol.
The pharmaceutical composition of claim 4, wherein the pharmaceutical composition contains 5 ppm or less of 6,7-dimethoxy-quinoline-4-ol.
A method of treating cancer, comprising administering to a subject in need thereof a pharmaceutical composition comprising Compound IB:
- and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is a tablet or a capsule, and wherein the pharmaceutical composition contains 100 ppm or less of 6,7-dimethoxy-quinoline-4-ol.
The method of claim 6, wherein the pharmaceutical composition contains 50 ppm or less of 6,7-dimethoxy-quinoline-4-ol.
The method of claim 7, wherein the pharmaceutical composition contains 25 ppm or less of 6,7-dimethoxy-quinoline-4-ol.
The method of claim 8, wherein the pharmaceutical composition contains 10 ppm or less of 6,7-dimethoxy-quinoline-4-ol.
The method of claim 9, wherein the pharmaceutical composition contains 5 ppm or less of 6,7-dimethoxy-quinoline-4-ol.
The method of claim 6, wherein the cancer is renal cancer.
The method of claim 6, wherein the cancer is prostate cancer.
The method of claim 6, wherein the cancer is hepatocellular carcinoma.
The method of claim 7, wherein the cancer is renal cancer.
The method of claim 7, wherein the cancer is prostate cancer.
The method of claim 7, wherein the cancer is hepatocellular carcinoma.
The method of claim 8, wherein the cancer is renal cancer.
The method of claim 8, wherein the cancer is prostate cancer.
The method of claim 8, wherein the cancer is hepatocellular carcinoma.
The method of claim 9, wherein the cancer is renal cancer.
The method of claim 9, wherein the cancer is prostate cancer.
The method of claim 9, wherein the cancer is hepatocellular carcinoma.
Dependencies are inferred from the claim text.